Valeda LDS – Dry AMD treatment

Valeda LDS – the World’s first and only approved treatment, using Photobiomodulation for Dry Age-Related Macular Degeneration.

Scroll down or click on a specific below if you want to proceed to a specific Chapter.

Age-Related Macular Degeneration (AMD)
Valeda LDS treatment
First assessment and treatment schedule
Follow-up assessment and treatment schedule

Age-Related Macular Degeneration (AMD) is a gradual loss of vision that progresses with age. AMD normally affects central vision, particularly contrast sensitivity, dark adaptation, colour vision and depth perception – changes that influence performance and experience of day-to-day tasks and hobbies such as reading, driving, watching TV, painting etc.

Early stages of the disease tend to primarily affect the rods – the receptors responsible for night vision – these are not usually assessed in a routine sight test.

Due to the degenerative and progressive nature of the disease process and the incredible complexity of the human visual system and brain, dry AMD is only normally detected when the disease is already significantly advanced – when it has already started to affect the cones – the receptors responsible for high contrast, central and colour vision.

Also, in modern society we are constantly surrounded by artificial lighting, headlights, streetlamps etc. Hence often we are completely unaware of changes in night vision until there has been a significant and often life changing deterioration in our vision.


Photobiomodulation (PBM) is the application of different wavelengths of light, most commonly red and near-infrared light. PBM therapy improves metabolism within the mitochondria – organelles within cells that are responsible for energy production.

So far, research has shown that PBM therapy attenuates degeneration in sick retina and optic nerve cells, accelerates wound healing, and improves recovery from ischemic injury.

Valeda LDS treatment

The Valeda Light Delivery System (LDS) is the World’s first approved treatment for Dry AMD using PBM. You can be reassured that your treatment will be undertaken by the World’s first Optometrist and Optometric practice to offer this long awaited truly innovative treatment developed by LumiThera Inc. For more information, please see

The aim of this new treatment is to slow down the progression of the disease and if caught early enough to even improve your visual performance in day-to-day activities – so you can enjoy improved vision for longer, as well as enhanced quality of life!


The treatment plan commences with a Metropsis Visual Function assessment (Cambridge Research Systems), macular integrity assessment (MAIA) and a series of Heidelberg Spectralis Optical Coherence Tomography (OCT) and OCT Angiography scans and images of the retina and macula following dilation (drops). These assessments facilitate the close monitoring of your progress and the ongoing effects and benefits of the Valeda LDS treatment over time.

We will investigate this in a unique way that is completely different to any other eye examination and any assessments that you may have experienced to date.

Assessment itinerary:

Visual Acuity – measures clarity of vision

Early Treatment Diabetic Retinopathy Study Chart

Landolt C

Macular Integrity Assessment (MAIA) – measures retinal sensitivity and fixation stability

Image of the retina

Dimness of seen light

Fixation Stability

3. Colour Discrimination – measures discrimination of low saturated colours

Cambridge Colour Assessment

4.Spatial Contrast – measures sensitivity to contrast

Gabor Patches

Temporal Contrast – measures sensitivity to movement

Gaussian Blob

5. Dark Adaptation – measures sensitivity of the rods (‘night vision’)

Gabor Patches

Before the Dark Adaptation assessment you will need to adapt to complete darknessk in order to activate your rod function. This involves sitting in a darkened room wearing a black out mask for 30 minutes. During this adaptation period you will be asked various lifestyle questions as part of a validated questionnaire.

Installation of dilating eye drops

6. Optical Coherence Tomography – 4D HD optical imaging

Blue Peak Auto Fluorescence image

OCT Angiography of Macula

High Density OCT

It takes up to 5 hours to complete the first assessment.

NOTE: the purpose of the assessments is not to ‘pass’ or ‘fail’ but to establish a reliable baseline and enable accurate follow ups on the effectiveness of the treatment and development in your case.

If further diagnostic appointments are required after the initial assessment to establish a reliable baseline then this will be done at a reduced fee £150 instead of £450.

It is important during the assessment to ensure that you are prepared and comfortable. Make sure you have had a “comfort break” and please turn your digital devices off.

First assessment and treatment schedule


A thorough visual assessment (up to 5 hours, including dilation): this will be preferably undertaken with up to date visual correction, spectacles or contact lenses.


On your first appointment you will undergo all of the assessments in the Assessments section.


The second and third appointments consists of repeating the Assessments – this is essential to establish a reliable baseline with which we will monitor all measurable changes to your vision and the efficacy of the treatment (up to 3 hours, no dilation).


Immediately after your third assessment you can proceed (if convenient) with the first Valeda LDS session. Overall, you will have 9 Valeda LDS sessions (20 minutes appointment). We recommend appointments are spread over a 2-3 week period for optimum results.


For international/long-distance clients. This appointment will take up to 5 hours as it will incorporate a final assessment (including dilation). This compromises a repeat of the initial diagnostic steps (Assessments). Once the treatment cycle is completed, the results will be analysed. Within 4 weeks, you will receive a detailed Report.

Local clients attend a 9th Valeda LDS treatment session as previous sessions. You will be invited for a final assessment one month after your 9th Valeda LDS treatment session. This appointment will take up to 5 hours (including dilation). You will repeat all initial diagnostic steps (Assessments).

After completion your results will be analysed, and you will receive a detailed Report within 4 weeks

Note, all appointments need to be scheduled and diarised in advance in order to guarantee availability.

Follow-up assessment and treatment schedule

If your visual performance is stable or there is an improvement, and you are satisfied with the treatment and wish to continue, we would then schedule a follow-up treatment. LumiThera Inc. (manufacturer of the Valeda LDS), based on the clinical trials, recommend repeating the treatment every 4 – 6 months. However, it may in early cases only be necessary to treat on an annual basis with a six-monthly assessment to monitor progression or as recommended.

Here you can set a Direct Debit which will pay for the next set of treatments and diagnostics (Fees).


Follow-up treatment cycles usually consist of one baseline assessment session (Assessments), up to 5 hours, including dilation. Your 1st Valeda LDS session can be scheduled on the same day of the baseline assessment. Further you will have 8 more treatment sessions and your final assessment to monitor your progress and effectiveness of Valeda LDS treatment.

Note, appointments need to be scheduled and diarised in advance in order to guarantee availability.


Treatment of both eyes Treatment of one eye
First treatment cycle and diagnostics £1350 £1150
Follow-up treatment cycle £990 £790
If for any reason you are unable to proceed with the treatment after the initial appointment or you decide not to proceed, a fee of £450 is payable for the diagnostics, and the balance will be refunded.
If further diagnostic appointments are required after the initial assessment to establish a reliable baseline then this will be done at a reduced fee £150 instead of £450.
The above costs are for the diagnostics and treatment only – this assessment and treatment is specifically aimed at treating and monitoring dry AMD, and does not include a refraction or a sight test or any type of ‘normal’ eye examination.
The treatment is currently not funded by NHS.
If an existing client wants to include into the direct debit an element for eye exams etc. then we can add this to the direct debit starting from only an extra £12 per month cost, depending on complexity of client (Note, it would normally be from £20 per month).